%0 Journal Article %T Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination %+ Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)) %+ Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163) %+ Rockefeller University [New York] %+ Institut Mondor de Recherche Biomédicale (IMRB) %+ Virologie Structurale - Structural Virology %+ CHU Henri Mondor [Créteil] %+ Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven) %+ INSERM U955, team 2. Mondor Biomedical Research Institute, Paris-Est Créteil University, Créteil, France. Departement of Internal Medicine, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France %+ Centre Hospitalier Universitaire d'Angers (CHU Angers) %+ Université d'Angers (UA) %+ AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre) %+ Université Paris-Saclay %+ Hôpital Nord Franche-Comté [Hôpital de Trévenans] (HNFC) %+ Service de pédiatrie [CHRU Besançon] %+ AP-HP. Nord - Université Paris Cité %+ Hôpital Lariboisière-Fernand-Widal [APHP] %+ Centre Hospitalier Universitaire de Nancy (CHU Nancy) %+ Hôpital Mère-Enfant [Hôpital Hôtel Dieu, Nantes] %+ Université libre de Bruxelles (ULB) %+ Hôpital Robert Debré %+ Centre Hospitalier le Vinatier [Bron] %+ Hospital Universitario Infanta Leonor [Madrid] %+ Institut d'Investigació Biomèdica de Bellvitge [Barcelone] (IDIBELL) %+ Université Paris Cité (UPCité) %+ Université de Versailles Saint-Quentin-en-Yvelines (UVSQ) %+ Etablissement Français du Sang [La Plaine Saint-Denis] (EFS) %+ Sydney Children's hospital %+ University of New South Wales [Sydney] (UNSW) %+ Children’s Health Queensland [Brisbane] (CHQ) %+ CHU Necker - Enfants Malades [AP-HP] %+ Universidad Fernando Pessoa Canarias [Las Palmas de Gran Canaria, Spain] %+ Garvan Institute of medical research %+ Howard Hughes Medical Institute [New York] (HHMI) %A Sokal, Aurélien %A Bastard, Paul %A Chappert, Pascal %A Barba-Spaeth, Giovanna %A Fourati, Slim %A Vanderberghe, Alexis %A Lagouge-Roussey, Pauline %A Meyts, Isabelle %A Gervais, Adrian %A Bouvier-Alias, Magali %A Azzaoui, Imane %A Fernández, Ignacio %A de la Selle, Andréa %A Zhang, Qian %A Bizien, Lucy %A Pellier, Isabelle %A Linglart, Agnès %A Rothenbuhler, Anya %A Marcoux, Estelle %A Anxionnat, Raphael %A Cheikh, Nathalie %A Léger, Juliane %A Amador-Borrero, Blanca %A Fouyssac, Fanny %A Menut, Vanessa %A Goffard, Jean-Christophe %A Storey, Caroline %A Demily, Caroline %A Mallebranche, Coralie %A Troya, Jesus %A Pujol, Aurora %A Zins, Marie %A Tiberghien, Pierre %A Gray, Paul %A Mcnaughton, Peter %A Sullivan, Anna %A Peake, Jane %A Levy, Romain %A Languille, Laetitia %A Rodiguez-Gallego, Carlos %A Boisson, Bertrand %A Gallien, Sébastien %A Neven, Bénédicte %A Michel, Marc %A Godeau, Bertrand %A Abel, Laurent %A Rey, Felix %A Weill, Jean-Claude %A Reynaud, Claude-Agnès %A Tangye, Stuart %A Casanova, Jean-Laurent %A Mahévas, Matthieu %Z Funder(s): Agence Nationale de la Recherche Award Id(s): ANR-21-RHUS-0008, ANR-10-IAHU-01, ANR-10-LABX-62-IBEID , ANR-20-CE93-003Funder(s): Fondation pour la Recherche MédicaleAward Id(s): MEMO-COV-2-FRMFunder(s): Institut PasteurFunder(s): Agence Nationale de Recherches sur le Sida et les Hépatites ViralesFunder(s): Howard Hughes Medical InstituteFunder(s): Rockefeller UniversityFunder(s): St. Giles FoundationFunder(s): National Institutes of Health Award Id(s): R01AI088364, R01AI163029, UL1TR001866Funder(s): National Center for Advancing Translational SciencesFunder(s): Fisher Center for Alzheimer’s Research FoundationFunder(s): Meyer FoundationFunder(s): JPB FoundationFunder(s): French Foundation for Medical Research Award Id(s): EQU201903007798, EA20170638020Funder(s): European Union’s Horizon 2020 Award Id(s): 824110Funder(s): Square FoundationFunder(s): Fondation du SouffleFunder(s): French Ministry of Higher Education, Research, and Innovation Award Id(s): MESRI-COVID-19Funder(s): Institut National de la Santé et de la Recherche MédicaleFunder(s): Fondation Bettencourt SchuellerFunder(s): CSL BehringFunder(s): KU Leuven Award Id(s): C16/18/007Funder(s): http://dx.doi.org/10.13039/501100003130 Award Id(s): G0C8517N, G0B5120N, G0E8420NFunder(s): Jeffrey Modell FoundationFunder(s): National Health and Medical Research Council Award Id(s): 1176665Funder(s): Allergy and Immunology Foundation of AustraliaFunder(s): John Brown Cook FoundationFunder(s): Fondation Princesse GraceFunder(s): Comité ad-hoc de pilotage national des essais thérapeutiques et autres recherchesFunder(s): Assistance Publique—Hôpitaux de Paris Award Id(s): MEMO-COV-2Funder(s): Société Nationale de Médecine InterneFunder(s): ANRS Nord-Sud Award Id(s): ANRS-COV05Funder(s): ANR-RHU Award Id(s): ANR-21-RHUS-08 (COVIFERON)Funder(s): HORIZON-HLTH-2021-DISEASE-04 Award Id(s): 01057100Funder(s): Grandir - Fonds de solidarité pour l’enfanceFunder(s): SCOR Corporate Foundation for ScienceFunder(s): REACTing-INSERMFunder(s): University of Paris CitéFunder(s): Imagine InstituteFunder(s): VIB GC PIDFunder(s): European Research Council Award Id(s): ERC-StG MORE2ADA2 %< avec comité de lecture %@ 0022-1007 %J Journal of Experimental Medicine %I Rockefeller University Press %V 220 %N 1 %P e20220258 %8 2023-01-02 %D 2023 %R 10.1084/jem.20220258 %M 36342455 %Z Life Sciences [q-bio]/Immunology %Z Life Sciences [q-bio]/Immunology/VaccinologyJournal articles %X Inborn and acquired deficits of type I interferon (IFN) immunity predispose to life-threatening COVID-19 pneumonia. We longitudinally profiled the B cell response to mRNA vaccination in SARS-CoV-2 naive patients with inherited TLR7, IRF7, or IFNAR1 deficiency, as well as young patients with autoantibodies neutralizing type I IFNs due to autoimmune polyendocrine syndrome type-1 (APS-1) and older individuals with age-associated autoantibodies to type I IFNs. The receptor-binding domain spike protein (RBD)–specific memory B cell response in all patients was quantitatively and qualitatively similar to healthy donors. Sustained germinal center responses led to accumulation of somatic hypermutations in immunoglobulin heavy chain genes. The amplitude and duration of, and viral neutralization by, RBD-specific IgG serological response were also largely unaffected by TLR7, IRF7, or IFNAR1 deficiencies up to 7 mo after vaccination in all patients. These results suggest that induction of type I IFN is not required for efficient generation of a humoral response against SARS-CoV-2 by mRNA vaccines. %G English %2 https://pasteur.hal.science/pasteur-03847416/document %2 https://pasteur.hal.science/pasteur-03847416/file/jem_20220258.pdf %L pasteur-03847416 %U https://pasteur.hal.science/pasteur-03847416 %~ PASTEUR %~ CNRS %~ UNIV-ANGERS %~ APHP %~ OPENAIRE %~ IMRB %~ UPEC %~ UNAM %~ UVSQ %~ UNIV-PARIS-SACLAY %~ CHU-UNIV-PARIS5 %~ UNIV-PARIS %~ UNIVERSITE-PARIS %~ UP-SANTE %~ UVSQ-UPSACLAY %~ UNIVERSITE-PARIS-SACLAY %~ ANR %~ FRM %~ VIR-STRUCT %~ PASTEUR_UMR3569